共 50 条
- [1] VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor (CDK4/6i)-resistant advanced solid tumorsGYNECOLOGIC ONCOLOGY, 2023, 176 : S173 - S173Yap, TimothyPatel, ManishHenick, BrianMoore, KathleenLeary, AlexandraDo, DoreenChapman, JoshZhang, HuiRoche, MariaNewberry, KateRinne, MikaelJuric, Dejan
- [2] A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumorsANNALS OF ONCOLOGY, 2022, 33 (07) : S765 - S765Yap, T. A.Moore, K. N.Patel, M.Henick, B. S.Do, D.Iheanacho, A.Zhang, H.Roche, M.Newberry, K.Hsieh, A.Juric, D.
- [3] BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Patel, Manish R.Juric, DejanHenick, Brian S.Duska, Linda R.Wu, RentianGuo, JianZhang, HuiNewberry, KateRinne, MikaelYap, Timothy A.
- [4] First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Wang, Yong-ShengJiang, YuSun, MeiliLiang, XuLi, Huiping
- [5] BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer modelsCANCER RESEARCH, 2022, 82 (12)Brown, VictoriaRamsden, PhilHouse, NealiaVargas, RichardGuo, JianWang, RuduanLobbardi, RiadhChen, MaxineWilson, DouglasKim, JosephBifulco, NeilMaynard, MichellePerola, EmanueleZhang, DeanWenglowsky, SteveChoi, Yoon Jong
- [6] Estrogen-induced activation of Cdk4 and Cdk2 during G(1)-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (16) : 10882 - 10894Prall, OWJSarcevic, BMusgrove, EAWatts, CKWSutherland, RL
- [7] First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2-breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Yap, Timothy A.Elhaddad, Abdelaziz M.Grisham, Rachel N.Hamm, John TurnerMarks, Douglas KanterShapiro, GeoffreyLe Corre, ChristopheLi, JerryLin, Tun TunLiu, FengMalky, LaraMoreau, Allison R.Neumann, HeatherJuric, DejanSharma, Manish
- [8] Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitorsJOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2005, 19 (02) : 111 - 122Rossi, KAMarkwalder, JASeitz, SPChang, CHCox, SBoisclair, MDBrizuela, LBrenner, SLStouten, PFW
- [9] Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial TumorsCANCER RESEARCH, 2025, 85 (07) : 1297 - 1309House, Nealia C.Brown, Victoria E.Chen, MaxineYuan, LiangMoore, Sydney L.Guo, JianChoi, Yoon JongMuthuswamy, LakshmiRibich, ScottRamsden, PhilipFaia, Kerrie L.
- [10] Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitorsJournal of Computer-Aided Molecular Design, 2005, 19 : 111 - 122Karen A. RossiJay A. MarkwalderSteven P. SeitzChong-Hwan ChangSarah CoxMichael D. BoisclairLeonardo BrizuelaStephen L. BrennerPieter F. W. Stouten